Anti-CCR8 antibody or antigen binding fragment thereof
Patent Information
- Application Number
- CN202380032440.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-07
- Filing Date
- 2023-04-06
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-04-06
AI Technical Summary
The CCR8 chemokine receptor exerts an immunosuppressive function in the tumor microenvironment. However, existing technologies are difficult to effectively target and block its signaling pathway, resulting in limited anti-tumor immune effects.
Develop an anti-CCR8 antibody or its antigen-binding fragment that specifically recognizes human CCR8 protein, blocks the signaling pathway between CCR8 and CCL1/CCL18, and targets CCR8-expressing cells through ADCC activity. The amino acid sequences of the heavy chain and light chain variable regions of the antibody or fragment are selected from specific sequences or similar sequences, with high identity or conservative variation, and are combined with the Fc region to enhance its function.
It achieves targeted recognition and blocking of CCR8-expressing cells, enhances the anti-tumor immune effect, blocks the signaling pathway between CCR8 and CCL1/CCL18, and significantly inhibits the proliferation and migration of tumor cells.
Smart Images

Figure CN118984839A_ABST
Abstract
Description
An anti-CCR8 antibody or antigen-binding fragment thereof Technical Field
[0001] The present invention belongs to the fields of tumor immunotherapy and molecular immunology, and specifically relates to an anti-CCR8 antibody or an antigen-binding fragment thereof. Background Art
[0002] Chemokine receptors (CPCRs) are seven-transmembrane G protein-coupled receptors (GPCRs) expressed on the surface of certain cells. Chemokine receptors bind to their extracellular ligands, chemokines, triggering calcium influx and chemotactic responses, thereby directing cells to specific sites in the body. The binding of CCR8 and its ligands CCL1 / CCL18 positively regulates the immunosuppressive function of the tumor microenvironment.
[0003] CCR8 (chemokine (CC motif) receptor 8) is a chemokine receptor highly expressed in tumor-infiltrating Treg cells. Its structure is similar to that of G-protein-coupled receptors and it is a seven-transmembrane protein. CCR8 is specifically expressed on tumor-infiltrating regulatory T cells (Tregs) but is largely absent on peripheral blood Tregs, regulating the immunosuppressive function of the tumor microenvironment. CCR8 activates the CCR8 receptor on cancer cells, leading to cancer cell proliferation, migration, and resistance to apoptosis. Furthermore, CCL1 can recruit Tregs to the tumor niche and induce the conversion of CD4+ T cells into Tregs.
[0004] There are four known CCR8 receptors: CCL1, CCL8, CCL16, and CCL18. The main receptor, chemokine CCL1, is upregulated at the site of inflammation. CCL1 can recruit FOXp3+CCR8+Treg cells to infiltrate into tumor tissues and exert immunosuppressive functions. At the same time, it can induce upregulation of CCR8 expression on the surface of FOXp3+Treg cells, inducing Ca 2+ Flow induces STAT3-dependent upregulation of Foxp3, CD39, IL-10, and granzyme B expression, thereby enhancing the immunosuppressive activity of these tumor-infiltrating Treg cells. Therefore, drugs targeting CCR8 can enhance anti-tumor immune effects by depleting tumor-infiltrating FOXp3+CCR8+ Treg cells or blocking the CCL1 / CCR8 pathway.
[0005] Summary of the Invention
[0006] The anti-CCR8 antibody developed by the present invention can specifically recognize human CCR8 protein, block the signaling pathway between CCR8 and CCL1 / CCL18, specifically recognize cells expressing CCR8, and has target-specific ADCC activity against target cells expressing CCR8.
[0007] The technical solution adopted in the present invention is as follows:
[0008] An anti-CCR8 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
[0009] (a) a heavy chain variable region HCDR1 selected from any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53;
[0010] (b) a heavy chain variable region HCDR2 selected from any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54;
[0011] (c) a heavy chain variable region HCDR3 selected from any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55;
[0012] (d) a light chain variable region LCDR1 selected from the group consisting of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to an amino acid sequence of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73;
[0013] (e) LCDR2 of the light chain variable region is selected from the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74, or sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74, or amino acid sequences that have one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74; and / or
[0014] (f) a LCDR3 of a light chain variable region selected from the group consisting of amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75, or sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75, or sequences that have one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to the amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75.
[0015] In an optional embodiment, the HCDR1, HCDR2, HCDR3 of the heavy chain variable region, and the LCDR1, LCDR2, LCDR3 of the light chain variable region of the anti-CCR8 antibody or antigen-binding fragment thereof are selected from any one of the following amino acid sequences (1) to (14):
[0016] (1) HCDR1 shown in SEQ ID NO: 2, HCDR2 shown in SEQ ID NO: 3, HCDR3 shown in SEQ ID NO: 4, LCDR1 shown in SEQ ID NO: 6, LCDR2 shown in SEQ ID NO: 7, LCDR3 shown in SEQ ID NO: 8;
[0017] (2) HCDR1 shown in SEQ ID NO: 10, HCDR2 shown in SEQ ID NO: 11, HCDR3 shown in SEQ ID NO: 12, LCDR1 shown in SEQ ID NO: 14, LCDR2 shown in SEQ ID NO: 15, LCDR3 shown in SEQ ID NO: 16;
[0018] (3) HCDR1 shown in SEQ ID NO: 18, HCDR2 shown in SEQ ID NO: 19, HCDR3 shown in SEQ ID NO: 20, LCDR1 shown in SEQ ID NO: 22, LCDR2 shown in SEQ ID NO: 23, LCDR3 shown in SEQ ID NO: 24;
[0019] (4) HCDR1 shown in SEQ ID NO: 26, HCDR2 shown in SEQ ID NO: 27, HCDR3 shown in SEQ ID NO: 28, LCDR1 shown in SEQ ID NO: 30, LCDR2 shown in SEQ ID NO: 31, LCDR3 shown in SEQ ID NO: 32;
[0020] (5) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 57, LCDR2 shown in SEQ ID NO: 58, LCDR3 shown in SEQ ID NO: 59;
[0021] (6) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 61, LCDR2 shown in SEQ ID NO: 62, LCDR3 shown in SEQ ID NO: 63;
[0022] (7) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67;
[0023] (8) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 57, LCDR2 shown in SEQ ID NO: 58, LCDR3 shown in SEQ ID NO: 59;
[0024] (9) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 61, LCDR2 shown in SEQ ID NO: 62, LCDR3 shown in SEQ ID NO: 63;
[0025] (10) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67;
[0026] (11) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 69, LCDR2 shown in SEQ ID NO: 70, LCDR3 shown in SEQ ID NO: 71;
[0027] (12) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 73, LCDR2 shown in SEQ ID NO: 74, LCDR3 shown in SEQ ID NO: 75;
[0028] (13) HCDR1 shown in SEQ ID NO: 49, HCDR2 shown in SEQ ID NO: 50, HCDR3 shown in SEQ ID NO: 51, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67;
[0029] (14) HCDR1 shown in SEQ ID NO: 53, HCDR2 shown in SEQ ID NO: 54, HCDR3 shown in SEQ ID NO: 55, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67.
[0030] In an optional embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
[0031] (a) the heavy chain variable region has any one of the amino acid sequences given in SEQ ID NO: 1, 9, 17, 25, 33, 34, 35, 36, 40, 44, 48, or 52,
[0032] or a sequence that is at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or more identical to the amino acid sequence set forth in SEQ ID NO: 1, 9, 17, 25, 33, 34, 35, 36, 40, 44, 48, 52,
[0033] or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 1, 9, 17, 25, 33, 34, 35, 36, 40, 44, 48, 52;
[0034] (b) the light chain variable region has any one of the amino acid sequences given in SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, or 72,
[0035] or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or more identity to the amino acid sequence given in SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, 72,
[0036] Or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, 72.
[0037] In an optional embodiment, the heavy chain variable region and light chain variable region of the anti-CCR8 antibody or antigen-binding fragment thereof are selected from any one of the following amino acid sequences (1) to (26):
[0038] (1) SEQ ID NO: 1 and SEQ ID NO: 5;
[0039] (2) SEQ ID NO: 9 and SEQ ID NO: 13;
[0040] (3) SEQ ID NO: 17 and SEQ ID NO: 21;
[0041] (4) SEQ ID NO: 25 and SEQ ID NO: 29;
[0042] (5) SEQ ID NO: 33 and SEQ ID NO: 37;
[0043] (6) SEQ ID NO: 33 and SEQ ID NO: 38;
[0044] (7) SEQ ID NO: 33 and SEQ ID NO: 39;
[0045] (8) SEQ ID NO: 34 and SEQ ID NO: 37;
[0046] (9) SEQ ID NO: 34 and SEQ ID NO: 38;
[0047] (10) SEQ ID NO: 34 and SEQ ID NO: 39;
[0048] (11) SEQ ID NO: 35 and SEQ ID NO: 37;
[0049] (12) SEQ ID NO: 35 and SEQ ID NO: 38;
[0050] (13) SEQ ID NO: 35 and SEQ ID NO: 39;
[0051] (14) SEQ ID NO: 36 and SEQ ID NO: 37;
[0052] (15) SEQ ID NO: 36 and SEQ ID NO: 38;
[0053] (16) SEQ ID NO: 36 and SEQ ID NO: 39;
[0054] (17) SEQ ID NO: 40 and SEQ ID NO: 56;
[0055] (18) SEQ ID NO: 40 and SEQ ID NO: 60;
[0056] (19) SEQ ID NO: 40 and SEQ ID NO: 64;
[0057] (20) SEQ ID NO: 44 and SEQ ID NO: 56;
[0058] (21) SEQ ID NO: 44 and SEQ ID NO: 60;
[0059] (22) SEQ ID NO: 44 and SEQ ID NO: 64;
[0060] (23) SEQ ID NO: 44 and SEQ ID NO: 68;
[0061] (24) SEQ ID NO: 44 and SEQ ID NO: 72;
[0062] (25) SEQ ID NO: 48 and SEQ ID NO: 64;
[0063] (26) SEQ ID NO: 52 and SEQ ID NO: 64.
[0064] In alternative embodiments, the antibody or antigen-binding fragment thereof comprises a murine antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, and / or a humanized antibody or antigen-binding fragment thereof.
[0065] In an optional embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof further comprises an Fc region, and the Fc region is selected from mouse IgG1, IgG2a, IgG2b and / or IgG3, or selected from rat IgG1, IgG2a, IgG2b and / or IgG2c.
[0066] In an alternative embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof further comprises an Fc region selected from human IgG1, IgG2, IgG3, and / or IgG4, or an Fc region amino acid sequence having one or more amino acid mutations (preferably substitutions, insertions, or deletions) relative to human IgG1, IgG2, IgG3, or IgG4. In an alternative embodiment, the Fc region can be engineered, for example, in a knob-in-hole configuration.
[0067] The present invention also provides a nucleic acid molecule encoding any of the above-mentioned anti-CCR8 antibodies or antigen-binding fragments thereof.
[0068] The present invention also provides a recombinant vector comprising the above nucleic acid molecule.
[0069] The present invention also provides a recombinant cell comprising the aforementioned nucleic acid molecule and / or the aforementioned recombinant vector and capable of expressing the anti-CCR8 antibody or antigen-binding fragment thereof.
[0070] The present invention also provides a multifunctional fusion protein comprising any of the above-mentioned anti-CCR8 antibodies or antigen-binding fragments thereof.
[0071] In an optional embodiment, the multifunctional fusion protein further comprises one or more second antibodies or antigen-binding portions thereof that specifically bind to other antigens.
[0072] In an alternative embodiment, the antigen bound to the second antibody or antigen-binding portion thereof is selected from a tumor-associated antigen (TAA) or an immune checkpoint.
[0073] In an optional embodiment, any of the above-mentioned anti-CCR8 antibodies or antigen-binding fragments thereof, or any of the above-mentioned multifunctional fusion proteins is used in the preparation of a medicament for treating and / or preventing and / or diagnosing a disease.
[0074] In an optional embodiment, the use is achieved by one or more of tumor immunotherapy, cell therapy and gene therapy.
[0075] In an optional embodiment, any of the above-mentioned anti-CCR8 antibodies or antigen-binding fragments thereof, or any of the above-mentioned multifunctional fusion proteins are used in the preparation of a drug for treating cancer.
[0076] In an alternative embodiment, the cancer is breast cancer, ovarian cancer, lung cancer, liver cancer, melanoma, glioblastoma, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, pancreatic cancer, colon cancer, cervical cancer or related tumors.
[0077] The present invention also provides a pharmaceutical composition comprising any of the above-mentioned anti-CCR8 antibodies or antigen-binding fragments thereof and an acceptable carrier, diluent or excipient.
[0078] The present invention also provides a pharmaceutical composition comprising any of the multifunctional fusion proteins described above and an acceptable carrier, diluent or excipient. Beneficial effects
[0079] The anti-CCR8 antibody developed by the present invention can specifically recognize human CCR8 protein, block the signaling pathway between CCR8 and CCL1 / CCL18, specifically recognize cells expressing CCR8, and has target-specific ADCC activity against target cells expressing CCR8.
[0080] the term
[0081] To aid in understanding the invention described herein, the following abbreviations and term definitions are provided.
[0082] The following abbreviations are used in this article:
[0083] CDR: complementarity determining region in the variable region of an antibody;
[0084] HCDR: complementarity determining region in the variable region of the antibody heavy chain;
[0085] LCDR: complementarity-determining region in the variable region of the antibody light chain;
[0086] FR: Antibody framework region, i.e., the amino acid residues in the antibody variable region excluding CDR residues;
[0087] ELISA: enzyme-linked immunosorbent assay;
[0088] FACS: fluorescence-activated cell sorting.
[0089] In this manual, the term "antibody" refers to a natural immunoglobulin or an immunoglobulin prepared by partial or complete synthesis. Antibodies can be reconstructed and separated from natural resources such as plasma or serum of the natural antibody, or the culture supernatant of hybridoma cells that produce the antibody, animal immune serum, or phage library screening. Alternatively, they can be synthesized partially or completely using techniques such as genetic recombination. Preferred antibodies include, for example, antibodies of the isotype of immunoglobulin or the subclasses of these isotypes. Known human immunoglobulins include 9 categories (isotypes) of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM. Among these isotypes, antibodies of the present invention can include IgG1, IgG2, IgG3, and / or IgG4.
[0090] The terms "antibody" and "immunoglobulin" are used interchangeably. As used herein, some antibodies are immunoglobulin molecules composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC). Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region is composed of three domains (CH1, CH2, and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL), or only a light chain constant region (CL). The light chain constant region is composed of a single domain, CL. The constant domain is not directly involved in binding the antibody to the antigen, but exhibits various effector functions, such as mediating the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can be further subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antigen-binding site.
[0091] The term "antigen-binding fragment" of an antibody refers to a polypeptide fragment of an antibody, such as a polypeptide fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen to which the full-length antibody is bound, and / or competes with the full-length antibody for specific binding to the antigen, and is also referred to as an "antigen-binding portion". Antigen-binding fragments of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical fragmentation of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, linear antibodies, nanobodies (e.g., technology from Ablynx), domain antibodies (e.g., technology from Domantis), and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to a polypeptide.
[0092] The term "polypeptide" refers to an amino acid chain of any length, regardless of modifications (e.g., phosphorylation or glycosylation). The term polypeptide includes proteins and fragments thereof. Polypeptides can be "exogenous," meaning they are "heterologous," i.e., foreign to the host cell being utilized, such as human polypeptides produced by bacterial cells. Polypeptides are disclosed herein as sequences of amino acid residues. Those sequences are written from left to right, in the direction of amino terminus to carboxyl terminus. Amino acid residue sequences are designated by three-letter or one-letter codes according to standard nomenclature as follows: alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V).
[0093] There are multiple methods / systems in the field to define and describe CDRs. These systems and / or definitions have been developed and refined over the years, including Kabat, Chothia, IMGT, AbM, and Contact. Kabat is the most commonly used and defines CDRs based on sequence variability; Chothia defines CDRs based on sequence variability based on the position of structural loop regions; the IMGT system defines CDRs based on sequence variability and position within the variable domain structure; AbM is based on the AbM antibody modeling software from Oxford Molecular and is a compromise between Kabat and Chothia; Contact defines CDRs based on the analysis of complex crystal structures and is similar to Chothia in many aspects.
[0094] The numbering of amino acid positions (eg, amino acid residues in the Fc region) and target regions (eg, CDRs) in the anti-CCR8 antibodies of the present invention uses the Kabat system.
[0095] Percent (%) amino acid sequence "identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be performed in various ways that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA package.
[0096] The term "monoclonal antibody" refers to a homogeneous antibody directed only against a specific antigenic epitope. Compared to conventional polyclonal antibody preparations that typically include different antibodies directed against different antigenic determinants (epitopes), each monoclonal antibody is directed against a single antigenic determinant on the antigen. The modifier "monoclonal" indicates the homogeneous character of the antibody and is not to be construed as requiring the antibody to be produced by any particular method. The monoclonal antibodies of the present invention are preferably produced by recombinant DNA methods or obtained by screening methods described elsewhere herein.
[0097] The term "murine antibody," as used herein, refers to a monoclonal antibody prepared according to the knowledge and skill in the art. In certain embodiments, these antibodies are prepared by injecting a test subject with an antigen, followed by isolation of hybridomas expressing antibodies with the desired sequence or functional properties. In certain embodiments, the desired murine antibody is obtained by screening a mouse immune library.
[0098] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can mitigate the immune response induced by the mouse antibody. In certain embodiments, chimeric antibodies are created by first establishing a hybridoma that secretes a mouse-specific monoclonal antibody. The variable region genes are then cloned from the mouse hybridoma cells. Furthermore, the human constant region genes are cloned as needed. The mouse variable region genes and human constant region genes are then linked to form a chimeric gene, which is then inserted into a human vector. Finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic cell culture system.
[0099] The term "humanized antibody" refers to an antibody comprising at least one humanized antibody chain (i.e., at least one humanized light chain or heavy chain). The term "humanized antibody chain" (i.e., "humanized immunoglobulin chain") refers to an antibody chain (i.e., a light chain or a heavy chain, respectively) having a variable region comprising a substantial variable framework region and complementarity determination of a human antibody. Regions (CDRs) substantially derived from non-human antibodies (e.g., at least one CDR, two CDRs, or three CDRs). In some embodiments, the humanized antibody chain further comprises a constant region (e.g., in the case of a light chain, one constant region or a portion thereof, in the case of a heavy chain, preferably three constant regions).
[0100] The term "host cell" refers to a cell that has been or is capable of being transformed with a nucleic acid sequence to express a selected gene of interest. The term includes the progeny of a parent cell, regardless of whether the progeny is identical in morphology or genetic makeup to the original parent cell, as long as the gene of interest is present in the progeny. Commonly used host cells include bacteria, yeast, and mammalian cells.
[0101] The term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors." BRIEF DESCRIPTION OF THE DRAWINGS
[0102] Figures 1a and 1b show the binding activity of mouse anti-CCR8 antibodies to CHOK1-CCR8 cells.
[0103] FIG2 shows the binding activity of chimeric anti-CCR8 antibodies to CHOK1-CCR8 cells.
[0104] FIG3 shows the ADCC effect results of chimeric anti-CCR8 antibodies.
[0105] FIG4 shows the inhibition of β-arestin release by mouse anti-CCR8 antibody on CCL1-activated Tango-H_CCR8-CHO-K1 cells.
[0106] FIG5 shows the in vivo efficacy data of mouse anti-CCR8 antibodies.
[0107] Figures 6a and 6b show the binding activity of humanized anti-CCR8 antibodies to CHOK1-CCR8 cells.
[0108] Figures 7a and 7b show the ADCC effect results of humanized anti-CCR8 antibodies.
[0109] FIG8 shows the inhibition of β-arestin release by humanized anti-CCR8 antibody on CCL1-activated Tango-H_CCR8-CHO-K1 cells. DETAILED DESCRIPTION
[0110] Example 1: Animal Immunization
[0111] CCR8-CHO-K1 cells overexpressing human CCR8 were constructed by lentiviral transduction of CHO cells. CCR8-284 cells were used as immunogens and 1×10 7 Balb / c mice were immunized with total cells. A second immunization was performed half a month after the first immunization, and then again every month. Negative serum was collected from the mice 3 days before immunization, and 50 μL of blood was collected by tail clipping 6 days after each immunization. Negative serum and immune serum were diluted in proportion (1:0.1K, 1:1K, 1:10K, 1:100K, 1:1000K, 1:10000K), and serum titers were tested using Cell-ELISA using CCR8-CHO-K1 cells overexpressing CCR8. When the titer results met the requirements and anti-human CCR8 antibodies were detected at a dilution of >1:10K, the spleen and lymph nodes of the rats could be harvested.
[0112] Example 2: Cell fusion
[0113] B lymphocytes and lymph node cells were obtained from Balb / c mice immunized four times with CCR8-293 cells. The spleen and lymph nodes were placed in a cell strainer, which was then placed in a 50 mL centrifuge tube. DMEM was added dropwise to the spleen, triturated, and a splenocyte suspension was prepared. The suspension was centrifuged at 1600 rpm for 10 minutes, and the supernatant was removed. B cells were resuspended in 2 mL of red blood cell lysis buffer and lysed at room temperature for 2 minutes. 30 mL of DMEM was added, mixed, and centrifuged at 1600 rpm for 10 minutes before counting.
[0114] Myeloma cells SP2 / 0 (ATCC) were passaged the day before fusion, allowing the cells to be in the logarithmic growth phase at the time of the experiment. Splenocytes and SP2 / 0 were mixed at a ratio of 2:1 and centrifuged at 1600 rpm for 10 minutes. The mixed cells were washed twice with fusion solution and centrifuged at 1600 rpm for 10 minutes. The final cell density was 1×10 7Cells were suspended in fusion medium at a concentration of 10 cells / mL. Within 5 minutes, the cell suspension was transferred to the fusion chamber of an electrofusion instrument (BTX; ECM 2001) for fusion. After fusion was complete, the cells were transferred from the fusion chamber to complete HAT medium and incubated at 37°C for 60 minutes. After incubation, the cells were plated into a 96-well plate containing feeder cells and cultured at 37°C in 5% CO2.
[0115] Example 3: Preliminary screening of positive clones by ELISA
[0116] After 7 days of culture, the fusion supernatant was screened. CCR8-CHO-K1 cells were plated into 96 ELISA plates (1.5×10 4 Cells were fixed with 4% paraformaldehyde and blocked with 2% BSA. The blocking solution was discarded and the plate was washed three times using a plate washer. 100 μL / well of the fusion supernatant was added to the blocked ELISA plate and incubated at 37°C for 1 hour. The remaining liquid was discarded. The plate was washed three times using a plate washer. 100 μL / well of goat anti-mouse secondary antibody-HRP (Abcam; Ab6789) was diluted in 0.5% BSA and incubated at 37°C. The plate was washed six times using PBST and patted dry on a tissue paper. 100 μL / well of Solarbio colorimetric solution (Solarbio; PR1200) was added to the plate. The plate was wrapped with aluminum foil and developed at 37°C in the dark. 1 mol / L HCl was added to terminate the color reaction. The plate was read at 450 nm on a microplate reader and the data were analyzed. The cell lines with OD450>1.0 in the supernatant were selected as the candidate positive cell lines for primary screening, the culture supernatant of the positive cell lines was discarded, and new HAT complete medium was added.
[0117] Example 4: Further screening of positive clones by FACS
[0118] Transfer CCR8-CHO-K1 cells to a centrifuge tube and centrifuge at 1000 rpm for 5 minutes. 5 Each stably expressing cell was aliquoted into separate tubes and 100 μL of fusion supernatant was added. The cells were incubated at 4°C for 60 minutes and then washed twice with excess FACS buffer. The cells were resuspended in 100 μL FACS buffer, and goat anti-mouse secondary antibody-FITC (Abcam; ab6785) was added to the sample, incubated for 30 minutes and washed twice with excess FACS buffer. The cells were fixed in fixation buffer and subsequently analyzed by flow cytometry. Antibodies that specifically bind to CCR8-CHO-K1 cells were screened by FACS.
[0119] Two rounds of limiting dilution were used to monoclone hybridoma cells, and ELISA was used to detect them. Monoclones with OD450>1.0 were selected as candidate cell lines for passage. For clones without monoclonal antibodies, clones with OD450>1.0 were selected for the next subcloning.
[0120] Example 5: Antibody Sample Production in Candidate Cell Lines
[0121] Culture hybridoma cells in a T75 cell culture flask until the cell confluence is 80-90%. Discard the supernatant from two flasks and add 30 mL of hybridoma-SFM to culture at 37°C in 5% CO2. Observe the cell status and culture medium color for 2-3 days. If the culture medium turns yellow, add 30 mL of fresh hybridoma-SFM. After 6-7 days of culture, centrifuge at low speed and collect the supernatant for purification.
[0122] Example 6: Binding activity of candidate antibodies to cells
[0123] Take the antibody to be tested and dilute it 5-fold with 6 gradients according to the initial and final concentration of 50 μg / mL. Take out the CCR8-CHO-K1 cells in the incubator, transfer the cell suspension to a 15 mL centrifuge tube, centrifuge, resuspend and count in PBS. Set aside the blank control group (Blank), negative control group (NC), experimental group, Yangshen group (Yangshen BMK is derived from the 1K17 sequence of US20210277129) and irrelevant antibody group. According to about 3×10 5 The cell suspension was plated in a 96-well plate.
[0124] After centrifugation (1000 rpm, 5 minutes), cells were washed with PBS and centrifuged again twice to remove residual culture medium. The supernatant was discarded. 100 μL of primary antibody solution and 100 μL of irrelevant antibody solution were added to the experimental and irrelevant antibody groups, respectively, and the cells were resuspended and incubated at room temperature for 1 hour. Blank and negative control groups were incubated with an equal volume of PBS.
[0125] After 1 hour, centrifuge and wash twice with PBS. After discarding the supernatant, except for the blank control group, which added 100 μL PBS, the remaining sample groups were added with 100 μL fluorescent secondary antibody dilution solution (mouse secondary antibody from Abcam ab6785), incubated at room temperature in the dark for 0.5 hour, centrifuged and washed twice with PBS. After discarding the supernatant, add 120 μL PBS to resuspend and perform flow cytometry to detect the average fluorescence intensity in sequence. The logarithm of the antibody concentration was taken as the horizontal axis, and the Sigmoidaldose-response (Variable Slope) method (GraphPadPrism software, GraphPadSoftware, San Diego, California) was used for nonlinear regression to obtain the antibody binding activity curve for CCR8-CHO cells. The results are shown in Figures 1a and 1b.
[0126] As can be seen from Figures 1a and 1b, the selected antibodies Ms-1, Ms-2, Ms-3, Ms-4, Ms-5, Ms-6, Ms-7, Ms-8, Ms-9, Ms-10, Ms-11, Ms-12, Ms-13, Ms-14 and Ms-15 all have good binding activity with CCR8-CHO, and the binding activity is better than that of yang ginseng and far better than that of yin ginseng.
[0127] Example 7: Sequencing of monoclonal antibodies
[0128] The hybridomas with good binding activity to the engineered cell CCR8-CHO obtained by FACs detection were sequenced, and the heavy chain variable regions and light chain variable regions of Ms-1, Ms-2, Ms-8 and Ms-15 were obtained respectively.
[0129] (1) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of the Ms-1 heavy chain variable region are SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively;
[0130] The amino acid sequence of the Ms-1 heavy chain variable region is SEQ ID NO: 1;
[0131] The amino acid sequences of LCDR1, LCDR2, and LCDR3 of the Ms-1 light chain variable region are SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively;
[0132] The amino acid sequence of the Ms-1 light chain variable region is SEQ ID NO:5.
[0133] (2) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of the Ms-2 heavy chain variable region are SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, respectively;
[0134] The amino acid sequence of the Ms-2 heavy chain variable region is SEQ ID NO: 9;
[0135] The amino acid sequences of LCDR1, LCDR2, and LCDR3 of the Ms-2 light chain variable region are SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;
[0136] The amino acid sequence of the Ms-2 light chain variable region is SEQ ID NO: 13.
[0137] (3) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of the Ms-8 heavy chain variable region are SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, respectively;
[0138] The amino acid sequence of the Ms-8 heavy chain variable region is SEQ ID NO: 17;
[0139] The amino acid sequences of LCDR1, LCDR2, and LCDR3 of the Ms-8 light chain variable region are SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24, respectively;
[0140] The amino acid sequence of the Ms-8 light chain variable region is SEQ ID NO: 21.
[0141] (4) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of the Ms-15 heavy chain variable region are SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28, respectively;
[0142] The amino acid sequence of the Ms-15 heavy chain variable region is SEQ ID NO: 25;
[0143] The amino acid sequences of LCDR1, LCDR2, and LCDR3 of the Ms-15 light chain variable region are SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32, respectively;
[0144] The amino acid sequence of the Ms-15 light chain variable region is SEQ ID NO: 29.
[0145] Example 8: Construction and expression of chimeric antibodies
[0146] The antibody fragments obtained by sequencing in Example 7 were gene synthesized and constructed into a human IgG framework. Then, using molecular cloning technology, the antibody fragments were inserted into the PCDNA3.1 vector to construct a mammalian cell expression plasmid. The plasmid was introduced into the host cell line CHO cells using liposome transfection. The fermentation supernatant was obtained using cell fed-batch, and the fermentation supernatant was purified by affinity chromatography to finally obtain the constructed chimeric antibodies: CH-1, CH-2, CH-8 and CH-15.
[0147] The amino acid sequences of the CDRs and variable domains of the chimeric antibodies CH-1, CH-2, CH-8 and CH-15 correspond to the amino acid sequences of the CDRs and variable domains of Ms-1, Ms-2, Ms-8 and Ms-15 in Example 7, respectively.
[0148] The amino acid sequences of the heavy chain constant regions of the chimeric antibodies CH-1, CH-2, CH-8 and CH-15 are all identical, as shown in SEQ ID NO: 76, and the amino acid sequences of the light chain constant regions are shown in SEQ ID NO: 77.
[0149] Example 9: Binding activity of chimeric antibodies
[0150] The binding activity of the chimeric antibody was detected by FACs method. The secondary antibody was PE F(ab')2 goat anti-human IgG Fc (Biolegend, Cat: 398004). The detection steps were the same as in Example 6. The results are shown in FIG2 .
[0151] As shown in Figure 2, chimeric antibodies CH-1, CH-2, CH-8 and CH-15 all have good binding activity with CCR8-CHO-K1 cells, which is comparable to the activity of Yangshen.
[0152] Example 10: ADCC activity of chimeric antibodies on target cells
[0153] CCR8-CHOK1 cells overexpressing human CCR8 were used as target cells, centrifuged at 1000 rpm for 4 minutes at room temperature, and resuspended in RPMI1640 basal medium (containing 5% FBS) at a concentration of 1×10 450 μL / well of antibody was plated in a 96-well plate. Antibody was diluted in RPMI1640 basal medium (containing 5% FBS) starting at 10 μg / mL, followed by 10-fold serial dilutions for a total of seven concentrations at 100 μL / well. NK cells were resuspended and added to the corresponding wells at 50 μL / well. The target cells were CCR8-CHOK1, with a target-effect ratio of 3:1. Wells for maximum target cell lysis (M), spontaneous release of target cells (ST), spontaneous release of effector cells (SE), a total volume correction blank well (BV), and a medium blank control well (BM) were also set. After 10 minutes of quiescence, the wells were centrifuged at 1000 rpm for 4 minutes at room temperature and incubated in a 5% CO2, 37°C CO2 cell culture incubator for 4 hours. Lysis buffer was added to wells M and BV 45 minutes in advance, mixed, and centrifuged at 1000 rpm for 4 minutes at room temperature after the incubation period. Pipette 50 μL of supernatant into the LDH assay plate, add 50 μL / well of substrate dissolved in assay buffer, react at room temperature in the dark for 30 minutes, add 50 μL / well of stop solution, let stand for 10 minutes, read at 490 nm, and calculate cell mortality.
[0154] The logarithm of the concentration of the constructed antibody was taken as the abscissa, and the Sigmoidal dose-response (Variable Slope) method (GraphPad Prism software, GraphPad Software, San Diego, California) was used for nonlinear regression to obtain the ADCC activity curve of the target antibody against target cells.
[0155] As shown in Figure 3, the IgG1 isotype control did not show killing of CCR8-CHOK1 cells, while the chimeric antibodies CH-1, CH-2, CH-8 and CH-15 and Yangshen showed lysis and death of CCR8-CHO-K1 cells in a concentration-dependent manner.
[0156] Example 11: Antagonistic activity of antibodies against CCL1
[0157] CCR8 is the only known receptor for CCL1. CCL1 binds to CCR8 on the cell surface, causing downstream signal transduction. Anti-CCR8 antibodies can inhibit this signal transduction pathway by blocking CCR8. Therefore, the ability of anti-CCR8 antibodies to block the CCL1-CCR8 pathway was tested, using β-arrestin as the target and Tango-H_CCR8-CHO-K1 (Yoshiman, GM-C13190). In brief, the activator Switch-On Reagent (Yoshiman, cat: GM-040501A) that induces CCR8 expression was added to Tango-H_CCR8-CHO-K1 cells, and after continuous culture for 48 hours, the cells were digested and collected by centrifugation at 200g, and the expression of ONE-Glo was detected. TM Resuspend the cells in the assay buffer of the Luciferase Assay System (Biolegend) at a cell concentration of 1.5 × 10 5 Cells / mL were added to a 96-well assay plate in a 100 μL volume and incubated overnight in a cell culture incubator. The antibody was diluted in assay buffer to a starting concentration of 15 μg / mL, followed by a 5-fold gradient dilution for a total of nine concentrations, and 50 μL / well was incubated for 1 hour. 50 μL of CCL1 (Biolegend) was then added as an activator to a final concentration of 0.06 μg / mL. After incubation for 7 hours, fluorescence values were read on a microplate reader. The logarithm of the constructed antibody concentration was used as the horizontal axis, and nonlinear regression was performed using the Sigmoidaldose-response (Variable Slope) method (GraphPad Prism software, GraphPad Software, San Diego, California) to obtain an inhibition curve for the target antibody against the downstream signaling molecule β-arrestin triggered by binding of CCL1 to CCR8.
[0158] The results are shown in Figure 4. IgG1, the isotype control group, was unable to inhibit the signal value of CCL1 activating β-arrestin. All candidate antibodies showed antagonistic activity in a concentration-dependent manner.
[0159] Example 12: In vivo efficacy experiment of mouse antibodies
[0160] Construction of humanized CCR8 C57 mice (Biocytogenin, C57BL / 6-CCR8 tm1(CCR8) The in vivo antitumor efficacy of antibodies Ms-2 and Ms-15 was evaluated in a subcutaneous colon cancer MC38 cell model (Bcgen). MC38 cells were revived, cultured, and digested to prepare a cell suspension. When the cells reached the logarithmic growth phase, they were harvested and the tumor cell suspension was injected subcutaneously into Balb / C nude mice. Each mouse was inoculated with 100 μL of cell suspension containing 5×105 Tumor growth was observed. When subcutaneous tumors reached approximately 100 mm³, animals were randomly divided into groups based on tumor volume and treated with CCR8 antibodies. The experimental indicator was whether tumor growth was inhibited, delayed, or cured. Tumor diameter was measured with a vernier caliper three times a week. Tumor volume was calculated as: V = 0.5a × b 2 , a and b represent the long diameter and short diameter of the tumor, respectively. The tumor-bearing mice were intraperitoneally injected with antibodies and PBS, twice a week, 10.0 mg / kg each time, for a total of 5 times.
[0161] The tumor inhibition efficacy of the compound was evaluated using the TGI (%). The TGI (%) was calculated as follows: TGI (%) = [1 - (average tumor volume of a treatment group at the end of dosing - average tumor volume of the treatment group at the start of dosing) / (average tumor volume of the solvent control group at the end of treatment - average tumor volume of the solvent control group at the start of treatment)] × 100%.
[0162] Figure 5 shows the tumor growth curves of hCCR8-bearing mice treated with antibodies in a subcutaneous MC38 colon cancer model. The horizontal axis represents the number of days after treatment, and the vertical axis represents tumor volume. Candidate antibodies Ms-2 and Ms-15 demonstrated significant tumor inhibition, significantly outperforming both the PBS and positive control groups, with tumor inhibition rates (TGI) exceeding 50%.
[0163] Example 13: Evaluation of humanized monoclonal antibodies
[0164] The variable region of the chimeric antibody is humanized. The design principle is to avoid the introduction of protein modification sites such as glycosylation, deamidation, isomerization, integrin binding sites, and cysteine. The back mutation of important amino acids in the framework region should maintain the original physical and biochemical activity. The specific method is as follows:
[0165] The mouse sequences Ms-15 and Ms-2 were aligned with the human germline sequence using the IgBLAST tool, and the FRs were replaced with the human germline sequence with the highest sequence similarity. The Ms-2 heavy chain design template selected the IGHV1 class, and the light chain design template selected the IGKV3 class. The Ms-15 heavy chain design template selected the IGHV3 class, and the light chain design template selected the IGKV3 class, resulting in the humanized antibody sequence. Based on this humanization, several important amino acids that affect antibody affinity were backmutated to the original mouse FR sites. The humanization percentage is the ratio of similarity between the designed sequence framework and the germline sequence framework. The designed humanized sequence was aligned with the human germline sequence, and sequences with a humanization percentage of at least 90% were selected.
[0166] The heavy chain sequence of the chimeric antibody CH-2 was designed into four humanized sequences, namely Hu-2-H1, Hu-2-H2, Hu-2-H3 and Hu-2-H4, among which the amino acid sequences of HCDR1, HCDR2 and HCDR3 were SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
[0167] The light chain sequence of the chimeric antibody CH-2 was designed into three humanized sequences, namely Hu-2-L1, Hu-2-L2 and Hu-2-L3, among which the amino acid sequences of LCDR1, LCDR2 and LCDR3 were SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, respectively.
[0168] The amino acid sequences of the variable regions of the above four heavy chains and three light chains are shown in Table 1, respectively.
[0169] Table 1
[0170] The above four humanized heavy chains and three humanized light chains were combined into 12 antibodies, as shown in Table 2.
[0171] Table 2
[0172] The chimeric antibody CH-15 heavy chain was designed with a humanized sequence containing a DS (aspartate isomerization risk) in the CDR2. The DS in the humanized sequence was mutated to ES, and a separate heavy chain with a back mutation was designed. The heavy chain CDR3 also contains an RGD (integrin binding site). During design, the RGD was mutated to RGE and RAD, respectively, based on the back mutation sequence, adding two chains, for a total of four chains: Hu-15-H1p1, Hu-15-H2p1, Hu-15-H2p1p2, and Hu-15-H2p1p3.
[0173] The CDR1 of the CH-15 light chain contains an NG (glycosylation risk). During the design, NG was mutated into QG and NA based on the maximum number of back mutations. A total of five light chains were designed, namely Hu-15-L1, Hu-15-L2, Hu-15-L3, Hu-15-L3p1 and Hu-15-L3p2.
[0174] The amino acid sequences of the variable regions and CDRs of the above four heavy chains and five light chains are shown in Table 3, respectively.
[0175] Table 3
[0176] The above 4 heavy chains and 5 light chains were combined to form 10 antibodies as shown in Table 4.
[0177] Table 4
[0178] The amino acid sequences in Table 3 were synthesized, and the above humanized sequence combinations were expressed. Construction and expression were performed according to the aforementioned method to prepare the humanized antibodies in Table 4.
[0179] The binding activity of the humanized antibody was evaluated according to the steps of Example 6, and the results are shown in Figures 6a and 6b. The results show that the humanized antibody has good binding activity to CHOK1-CCR8 cells, comparable to that of the chimeric antibody and BMK (derived from the 1K17 sequence of US20210277129), and far superior to unrelated antibodies.
[0180] The ADCC activity of the humanized antibodies was evaluated according to the steps of Example 10, and the results are shown in Figures 7a and 7b. The results show that the humanized antibodies Hu-2-Z4, Hu-2-Z6, Hu-2-Z9, Hu-15-Z1, Hu-15-Z3, and Hu-15-Z6 have good ADCC activity, and their cell lysis rates are comparable to those of chimeric antibodies and BMK (derived from the 1K17 sequence of US20210277129), and are far superior to those of unrelated antibodies.
[0181] The antagonist activity of the humanized antibodies against the CCR-CCL1 signaling pathway was evaluated according to the procedure of Example 11, and the results are shown in Figure 8. The results show that all candidate antibodies exhibited antagonistic activity in a concentration-dependent manner, while the IgG isotype control was unable to inhibit the signal value of CCL1 activating β-arrestin.
Claims
1. An anti-CCR8 antibody or an antigen-binding fragment thereof, characterized in that: The antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein: (a) a heavy chain variable region HCDR1 selected from any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 2, 10, 18, 26, 41, 45, 49, or 53; (b) a heavy chain variable region HCDR2 selected from any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 3, 11, 19, 27, 42, 46, 50, or 54; (c) a heavy chain variable region HCDR3 selected from any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 4, 12, 20, 28, 43, 47, 51, and 55; (d) a light chain variable region LCDR1 selected from the group consisting of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73, or an amino acid sequence that has one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to an amino acid sequence of SEQ ID NO: 6, 14, 22, 30, 57, 61, 65, 69, or 73; (e) LCDR2 of the light chain variable region is selected from the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74, or sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74, or amino acid sequences that have one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the amino acid sequences of SEQ ID NO: 7, 15, 23, 31, 58, 62, 66, 70, 74; and / or (f) a LCDR3 of a light chain variable region selected from the group consisting of amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75, or sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75, or sequences that have one or more (preferably two or three) conservative amino acid mutations (preferably substitutions, insertions, or deletions) compared to the amino acid sequences of SEQ ID NOs: 8, 16, 24, 32, 59, 63, 67, 71, or 75.
2. The anti-CCR8 antibody or antigen-binding fragment thereof according to claim 1, wherein The HCDR1, HCDR2, HCDR3 of the heavy chain variable region, and the LCDR1, LCDR2, LCDR3 of the light chain variable region are selected from any one of the following amino acid sequences (1) to (14): (1) HCDR1 shown in SEQ ID NO: 2, HCDR2 shown in SEQ ID NO: 3, HCDR3 shown in SEQ ID NO: 4, LCDR1 shown in SEQ ID NO: 6, LCDR2 shown in SEQ ID NO: 7, LCDR3 shown in SEQ ID NO: 8; (2) HCDR1 shown in SEQ ID NO: 10, HCDR2 shown in SEQ ID NO: 11, HCDR3 shown in SEQ ID NO: 12, LCDR1 shown in SEQ ID NO: 14, LCDR2 shown in SEQ ID NO: 15, LCDR3 shown in SEQ ID NO: 16; (3) HCDR1 shown in SEQ ID NO: 18, HCDR2 shown in SEQ ID NO: 19, HCDR3 shown in SEQ ID NO: 20, LCDR1 shown in SEQ ID NO: 22, LCDR2 shown in SEQ ID NO: 23, LCDR3 shown in SEQ ID NO: 24; (4) HCDR1 shown in SEQ ID NO: 26, HCDR2 shown in SEQ ID NO: 27, HCDR3 shown in SEQ ID NO: 28, LCDR1 shown in SEQ ID NO: 30, LCDR2 shown in SEQ ID NO: 31, LCDR3 shown in SEQ ID NO: 32; (5) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 57, LCDR2 shown in SEQ ID NO: 58, LCDR3 shown in SEQ ID NO: 59; (6) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 61, LCDR2 shown in SEQ ID NO: 62, LCDR3 shown in SEQ ID NO: 63; (7) HCDR1 shown in SEQ ID NO: 41, HCDR2 shown in SEQ ID NO: 42, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67; (8) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 57, LCDR2 shown in SEQ ID NO: 58, LCDR3 shown in SEQ ID NO: 59; (9) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 61, LCDR2 shown in SEQ ID NO: 62, LCDR3 shown in SEQ ID NO: 63; (10) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67; (11) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 69, LCDR2 shown in SEQ ID NO: 70, LCDR3 shown in SEQ ID NO: 71; (12) HCDR1 shown in SEQ ID NO: 45, HCDR2 shown in SEQ ID NO: 46, HCDR3 shown in SEQ ID NO: 47, LCDR1 shown in SEQ ID NO: 73, LCDR2 shown in SEQ ID NO: 74, LCDR3 shown in SEQ ID NO: 75; (13) HCDR1 shown in SEQ ID NO: 49, HCDR2 shown in SEQ ID NO: 50, HCDR3 shown in SEQ ID NO: 51, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO: 67; (14) HCDR1 shown in SEQ ID NO: 53, HCDR2 shown in SEQ ID NO: 54, HCDR3 shown in SEQ ID NO: 55, LCDR1 shown in SEQ ID NO: 65, LCDR2 shown in SEQ ID NO: 66, LCDR3 shown in SEQ ID NO:
67.
3. The anti-CCR8 antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, wherein: (a) the heavy chain variable region has SEQ ID NO: 1, 9, 17, 25, 33, 34, 35, 36, 40, Any of the amino acid sequences given in 44, 48, and 52, or a sequence that is at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or more identical to the amino acid sequence set forth in SEQ ID NO: 1, 9, 17, 25, 33, 34, 35, 36, 40, 44, 48, 52, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NOs: 1, 9, 17, 25, 33, 34, 35, 36, 40, 44, 48, 52; (b) the light chain variable region has any one of the amino acid sequences given in SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, or 72, or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or more identity to the amino acid sequence given in SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, 72, Or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any one of the amino acid sequences of SEQ ID NO: 5, 13, 21, 29, 37, 38, 39, 56, 60, 64, 68, 72.
4. The anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that The heavy chain variable region and light chain variable region are selected from any one of the following amino acid sequences (1) to (26): (1) SEQ ID NO: 1 and SEQ ID NO: 5; (2) SEQ ID NO: 9 and SEQ ID NO: 13; (3) SEQ ID NO: 17 and SEQ ID NO: 21; (4) SEQ ID NO: 25 and SEQ ID NO: 29; (5) SEQ ID NO: 33 and SEQ ID NO: 37; (6) SEQ ID NO: 33 and SEQ ID NO: 38; (7) SEQ ID NO: 33 and SEQ ID NO: 39; (8) SEQ ID NO: 34 and SEQ ID NO: 37; (9) SEQ ID NO: 34 and SEQ ID NO: 38; (10) SEQ ID NO: 34 and SEQ ID NO: 39; (11) SEQ ID NO: 35 and SEQ ID NO: 37; (12) SEQ ID NO: 35 and SEQ ID NO: 38; (13) SEQ ID NO: 35 and SEQ ID NO: 39; (14) SEQ ID NO: 36 and SEQ ID NO: 37; (15) SEQ ID NO: 36 and SEQ ID NO: 38; (16) SEQ ID NO: 36 and SEQ ID NO: 39; (17) SEQ ID NO: 40 and SEQ ID NO: 56; (18) SEQ ID NO: 40 and SEQ ID NO: 60; (19) SEQ ID NO: 40 and SEQ ID NO: 64; (20) SEQ ID NO: 44 and SEQ ID NO: 56; (21) SEQ ID NO: 44 and SEQ ID NO: 60; (22) SEQ ID NO: 44 and SEQ ID NO: 64; (23) SEQ ID NO: 44 and SEQ ID NO: 68; (24) SEQ ID NO: 44 and SEQ ID NO: 72; (25) SEQ ID NO: 48 and SEQ ID NO: 64; (26) SEQ ID NO: 52 and SEQ ID NO: 64; 5. The anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, characterized in that: The antibodies or antigen-binding fragments thereof include murine antibodies or antigen-binding fragments thereof, chimeric antibodies or antigen-binding fragments thereof, and / or humanized antibodies or antigen-binding fragments thereof.
6. The anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, characterized in that: It further comprises an Fc region selected from mouse IgG1, IgG2a, IgG2b and / or IgG3, or selected from rat IgG1, IgG2a, IgG2b and / or IgG2c.
7. The anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, characterized in that: It further comprises an Fc region, which is selected from human IgG1, IgG2, IgG3 and / or IgG4, or an Fc region amino acid sequence having one or more amino acid mutations (preferably substitutions, insertions or deletions) compared with human IgG1, IgG2, IgG3, IgG4.
8. A nucleic acid molecule encoding the anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.
9. A recombinant vector comprising the nucleic acid molecule of claim 8.
10. A recombinant cell comprising the nucleic acid molecule of claim 8 and / or the recombinant vector of claim 9, and capable of expressing the anti-CCR8 antibody or antigen-binding fragment thereof. A multifunctional fusion protein comprising the anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7. The multifunctional fusion protein according to claim 11 , further comprising one or more second antibodies or antigen-binding portions thereof that specifically bind to other antigens.
13. The multifunctional fusion protein according to claim 12, wherein the antigen bound to the second antibody or its antigen-binding portion is selected from a tumor-associated antigen (TAA) or an immune checkpoint.
14. Use of the anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the multifunctional fusion protein according to any one of claims 11 to 13, in the preparation of a medicament for treating and / or preventing and / or diagnosing a disease.
15. The use according to claim 14, wherein the use is achieved by one or more of tumor immunotherapy, cell therapy and gene therapy.
16. Use of the anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the multifunctional fusion protein according to any one of claims 11 to 13 in the preparation of a medicament for treating cancer.
17. The use according to claim 16, wherein the cancer is breast cancer, ovarian cancer, lung cancer, liver cancer, melanoma, glioblastoma, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, pancreatic cancer, colon cancer, cervical cancer or related tumors.
18. A pharmaceutical composition comprising the anti-CCR8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7 and an acceptable carrier, diluent or excipient.
19. A pharmaceutical composition comprising the multifunctional fusion protein according to any one of claims 11 to 13 and an acceptable carrier, diluent or excipient.
Citation Information
Patent Citations
Combined use of Anti-CCR8 antibody and chemotherapeutic agent
WO2022004760A1
CCR8 antibody and application thereof
WO2022042690A1
